Status:
COMPLETED
CLEAR SYNERGY Neutrophil Substudy
Lead Sponsor:
NYU Langone Health
Collaborating Sponsors:
Population Health Research Institute
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Neutrophils.Hypersegmented | Bld-Ser-Plas
STEMI - ST Elevation Myocardial Infarction
Eligibility:
All Genders
19-110 years
Brief Summary
CLEAR SYNERGY is an international multi center 2x2 randomized placebo controlled trial of colchicine and spironolactone in patients with STEMI. Subjects enrolled in the main CLEAR SYNERGY trial will b...
Eligibility Criteria
Inclusion
- Patients who are randomized to the drug RCT portion of the CLEAR SYNERGY (OASIS 9) trial will be eligible for participation in this Neutrophil biomarker substudy.
Exclusion
- Use of anti-inflammatory agents (except aspirin)
- Active infection
Key Trial Info
Start Date :
March 4 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 9 2024
Estimated Enrollment :
322 Patients enrolled
Trial Details
Trial ID
NCT03874338
Start Date
March 4 2019
End Date
August 9 2024
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NYU School of Medicine
New York, New York, United States, 10016